TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8856838
Drug: Melatonin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 1.0 mg
Study: 6235249
Drug: Etodolac 400
Normalized name: etodolac 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 400 mg b.i.d.
Study: 6235249
Drug: Etodolac 600
Normalized name: etodolac 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 600 mg b.i.d.
Study: 6235249
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg q.i.d.
Study: 6235249
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg in the morning, 50 mg at noon, and 100 mg h.s.
Study: 6235249
Drug: Naproxen 375
Normalized name: naproxen 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 375 mg b.i.d.
Study: 29514163
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 2 mg/day for days 1-28 with regorafenib
Study: 26820395
Drug: Heracleum persicum
Normalized name: Heracleum hemsleyanum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heracleum persicum hydroalcoholic fruit extract (300 mg/day)
Study: 25634390
Drug: Nitroglycerin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin and lignocaine (3 ml solution) infiltrated subcutaneously at the site intended for puncture (Group NL)
Study: 20602795
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced movement therapy
Study: 10422354
Drug: Holding therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holding therapy
Study: 7768080
Drug: Felodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (2.5 to 20 mg) once daily
Study: 7768080
Drug: Felodipine (oral)
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine (oral)
Study: 1416266
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray, 100 micrograms per nostril twice a day
Study: 3998201
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg (single dose)
Study: 3998201
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg (multiple doses, 200 mg every six hours and 400 mg before retiring)
Study: 3998201
Drug: Acetaminophen 750
Normalized name: acetaminophen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 750 mg (single dose alone)
Study: 30786924
Drug: Melanoma-associated antibodies
Normalized name: (264-l-valine)melanocyte protein pmel 17 (human melanoma-associated me20 antigen)-(256-264)-peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma-associated antibodies (NY-ESO-1)
Study: 30786924
Drug: Melanoma-associated antibodies
Normalized name: (264-l-valine)melanocyte protein pmel 17 (human melanoma-associated me20 antigen)-(256-264)-peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma-associated antibodies (MelanA/MART1)
Study: 30786924
Drug: Melanoma-associated antibodies
Normalized name: (264-l-valine)melanocyte protein pmel 17 (human melanoma-associated me20 antigen)-(256-264)-peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma-associated antibodies (gp100)
Study: 30786924
Drug: Melanoma-associated antibodies
Normalized name: (264-l-valine)melanocyte protein pmel 17 (human melanoma-associated me20 antigen)-(256-264)-peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma-associated antibodies (TRP1/TYRP1)
Study: 30786924
Drug: Melanoma-associated antibodies
Normalized name: (264-l-valine)melanocyte protein pmel 17 (human melanoma-associated me20 antigen)-(256-264)-peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma-associated antibodies (TRP2/TYRP2)
Study: 29730186
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume (HV, 350 mL) water load
Study: 29730186
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume (LV, 50 mL) water load
Study: 20304499
Drug: CF101 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 (1 mg, orally, twice daily for 12 weeks)
Study: 20304499
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching vehicle-filled pills, orally, twice daily for 12 weeks)
Study: 19030213
Drug: GOS formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS formula (0.24 g/100 mL)
Study: 2964344
Drug: Erythromycin 2
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 2 percent gel
Study: 24001291
Drug: Pre-treatment predictors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment predictors
Study: 24001291
Drug: In-treatment predictors
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment predictors
Study: 18211998
Drug: Rectal acetaminophen
Normalized name: acetaminophen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal acetaminophen 40 mg kg(‐1)
Study: 18211998
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen 15 mg kg(‐1)
Study: 12757988
Drug: Repaglinide (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (2-4 mg/day)
Study: 12757988
Drug: Metformin (1500-2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1500-2500 mg/day)
Study: 10490724
Drug: Filgrastim (G‐CSF)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim (G‐CSF) administered subcutaneously at a dose of 5 microg/kg body weight/day from day +5 after PBSC infusion
Study: 10490724
Drug: Filgrastim (G‐CSF)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim (G‐CSF)
Study: 1770184
Drug: Psychostimulants (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychostimulants (two doses)
Study: 6792958
Drug: Isotonic intravenous
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic intravenous infusions of dextrose (IV)
Study: 31984655
Drug: eluxadoline 100
Normalized name: eluxadoline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eluxadoline 100 mg twice daily
Study: 23169470
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (2 capsules daily, 480 mg containing 1.2 mg of S-allylcysteine)
Study: 23169470
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (4 capsules daily, 960 mg containing 2.4 mg of S-allylcysteine)
Study: 23169470
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (1 capsule daily, 240 mg containing 0.6 mg of S-allylcysteine)
Study: 21215788
Drug: Chlorhexidine MMP-inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine MMP-inhibitor
Study: 17003731
Drug: Electromyographic (EMG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromyographic (EMG) responses from the facial nerve in experienced implant users (Nucleus 24)
Study: 10938684
Drug: Fibrinolytic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic agent (n = 43)
Study: 10938684
Drug: Anticoagulant agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant agent (n = 4)
Study: 10938684
Drug: Neuroprotective drugs
Normalized name: NEUROPROTECTIN D1
DrugBank: AP-001 (DB18511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroprotective drugs (n = 25)
Study: 10938684
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment expectations
Study: 8653992
Drug: Oral TPGS
Normalized name: TPGS
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral TPGS (2.6 IU/kg) with cyclosporine (10mg/kg)
Study: 8653992
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine (10mg/kg) without TPGS
Study: 1306665
Drug: Oral indomethacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral indomethacin, 1 mg/kg per dose, three times a day for 7 days
Study: 1306665
Drug: Oral chloramphenicol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloramphenicol, 30 mg/kg per day, in four divided doses for 7 days
Study: 1306665
Drug: Oral indomethacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral indomethacin, 1 mg/kg per dose, three times a day for 7 days (after chloramphenicol)
Study: 6391137
Drug: Poster contemplation
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poster contemplation with hypnotic induction
Study: 30020461
Drug: Combination detemir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination detemir plus liraglutide
Study: 18692358
Drug: Radioguided occult
Normalized name: Homalomena occulta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioguided occult lesion localization (ROLL) with intra-tumoral injection of Tc99m-labelled macro-aggregate albumin
Study: 18692358
Drug: Simultaneous sentinel
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous sentinel node biopsy with Tc99m-labelled nanocolloids via periareolar-subdermal injection
Study: 1416323
Drug: 857 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 857 mg/kg sodium polystyrene sulfonate in 4 mL water/g sodium polystyrene sulfonate (experimental)
Study: 10756963
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of 15 micrograms/kg cisatracurium followed after 4 min by 85 micrograms/kg cisatracurium
Study: 6092410
Drug: L5‐OH‐triptophan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: L5‐OH‐triptophan (20 mg iv)
Study: 6092410
Drug: L5‐OH‐triptophan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: L5‐OH‐triptophan (40 mg iv)
Study: 6092410
Drug: L5‐OH‐triptophan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L5‐OH‐triptophan (200 mg orally)
Study: 6092410
Drug: L5‐OH‐triptophan (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L5‐OH‐triptophan (400 mg orally)
Study: 6092410
Drug: Fluoxetine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (15 mg orally)
Study: 6092410
Drug: Fluoxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (30 mg orally)
Study: 6092410
Drug: Methysergide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methysergide (3 X 2.8 mg orally)
Study: 30281066
Drug: GBS III-TT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS III-TT conjugate vaccine
Study: 30281066
Drug: Tetanus diphtheria
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus diphtheria toxoid vaccine
Study: 11815957
Drug: TLC D‐99
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC D‐99 (75 mg/m(2))
Study: 11815957
Drug: Doxorubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (75 mg/m(2))
Study: 9952144
Drug: Fentanyl 3
Normalized name: FENTANYL 37.5MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 3 ng/ml
Study: 9952144
Drug: Fentanyl 6
Normalized name: FENTANYL 62.5MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 6 ng/ml
Study: 2248757
Drug: Bopindolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol (1 mg once daily)
Study: 31173341
Drug: Combined dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dose of 50-60 min of aerobic and resistance exercise (COMB)
Study: 31336456
Drug: Radiofrequency and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency and Ultrasound (RF/US) combined with a low calorie diet, administered twice a week for 5 weeks
Study: 23582868
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to another SSRI or venlafaxine, with or without the addition of cognitive behavior therapy (CBT)
Study: 17822340
Drug: Atomoxetine once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine once daily
Study: 9783935
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin
Study: 11483141
Drug: naltrexone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone treatment plus contingency management (CM)
Study: 11483141
Drug: naltrexone treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone treatment, CM, plus significant other involvement (SO)
Study: 11483141
Drug: standard naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard naltrexone treatment
Study: 9740088
Drug: MET +
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MET + DEX (10 mg*4 and 2 mg*1, orally)
Study: 9740088
Drug: TRO (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRO (5 mg*1, orally)
Study: 9740088
Drug: TRO +
Normalized name: Tromethamine
DrugBank: Tromethamine (DB03754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRO + MET (5 mg*1 and 10 mg*2, orally)
Study: 9740088
Drug: TRO +
Normalized name: Tromethamine
DrugBank: Tromethamine (DB03754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRO + MET + DEX (5 mg*1, 10 mg*2, and 2 mg*1, orally)
Study: 9740088
Drug: CHL +
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHL + DEX (25 mg*2 and 2 mg*1, orally)
Study: 9740088
Drug: TRO +
Normalized name: Tromethamine
DrugBank: Tromethamine (DB03754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRO + CHL (5 mg*1 and 12.5 mg*2, orally)
Study: 9740088
Drug: TRO +
Normalized name: Tromethamine
DrugBank: Tromethamine (DB03754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRO + CHL + DEX (5 mg*1, 12.5 mg*2, and 2 mg*1, orally)
Study: 16885182
Drug: Ibuprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1200 mg daily for 14 days)
Study: 14687223
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + SDD (20 mg bid)
Study: 14687223
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + placebo (20 mg bid)
Study: 9476468
Drug: Nicotine plus
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine plus cisapride (5 mg)
Study: 9476468
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (14 mg/day)
Study: 7958682
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g of fish oil per day
Study: 7958682
Drug: 5.1 g
Normalized name: POVIDONE-IODINE 5.1 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.1 g of fish oil per day
Study: 7958682
Drug: 7.7 g
Normalized name: somatropin 13 % (1 gram/7.7 gram) MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.7 g of fish oil per day
Study: 7958682
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g of fish oil per day (in subsequent study with 15 patients)
Study: 28589618
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% twice daily for 2 weeks, then moisturizer cream twice daily for 2 weeks
Study: 28589618
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% twice daily for 2 weeks, then once daily for another 2 weeks
Study: 28589618
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% twice daily for 4 weeks
Study: 20067513
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg alone
Study: 20067513
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg plus Ezetimibe 10 mg
Study: 18753727
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with amiodarone (100-200 mg/day) and enalapril (5 mg/day)
Study: 12207166
Drug: Iodized oil
Normalized name: ethiodized oil
DrugBank: Ethiodized oil (DB00965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized oil (200 mg iodine)
Study: 9105549
Drug: Cefodizime 1
Normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime 1 g b.i.d. (median 7 days) in study A
Study: 9105549
Drug: Cefodizime 2
Normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime 2 g once daily (median 6 days) in study B
Study: 15883432
Drug: Boiled and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boiled and mashed orange-fleshed sweet potato (OFSP), 125 g daily for 53 school days, providing 1031 retinol activity equivalents/d as beta-carotene.
Study: 21484965
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 or 10 mg/kg
Study: 8790023
Drug: Lamifiban (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamifiban (high doses)
Study: 8790023
Drug: Lamifiban (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamifiban (highest dose)
Study: 8790023
Drug: Lamifiban (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamifiban (all doses)
Study: 27407053
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of extended-release niacin with 40 mg of laropiprant daily
Study: 11037739
Drug: 5‐isosorbide‐mononitrate (5‐ISMN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐isosorbide‐mononitrate (5‐ISMN) 30 mg three times daily for 7 days
Study: 11037739
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of glyceryl trinitrate for 20 minutes
Study: 9354191
Drug: Oral 5-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-ASA 3 g/day
Study: 8247308
Drug: Nicardipine Retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine Retard (40 mg twice a day)
Study: 2880810
Drug: Nadolol +
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol + HCTZ 50 mg b.i.d.
Study: 2880810
Drug: Propranolol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol + HCTZ 50 mg b.i.d.
Study: 2880810
Drug: HCTZ 50
Normalized name: HCTZ 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 50 mg b.i.d. + placebo
Study: 30286851
Drug: Oxycodone (OXY)
Normalized name: oxycodone hydrochloride Oral Tablet [M-Oxy]
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone (OXY) 5 mg (Open CTR group)
Study: 30286851
Drug: Ibuprofen (IBU)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IBU) 600 mg (Open CTR group)
Study: 30286851
Drug: Acetaminophen (ACE)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (ACE) 500 mg (Open CTR group)
Study: 26813970
Drug: Combination marker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination marker including serum glycan profiles
Study: 24777164
Drug: Digital Rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Rectal Evacuation (DE)
Study: 24777164
Drug: Transanal Irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transanal Irrigation (TAI) with 500 ml
Study: 22406126
Drug: Senofilcon A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senofilcon A (ACUVUE® OASYS® with HYDRACLEAR® Plus) worn on a daily wear basis and replaced every 2 weeks
Study: 18390450
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (single drug formulations)
Study: 6547101
Drug: Day Nurse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day Nurse (single dose)
Study: 23092239
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo lozenges)
Study: 27708111
Drug: Zofenopril 60
Normalized name: Zofenopril
DrugBank: Zofenopril (DB13166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 60 mg plus acetylsalicylic acid (ASA) 100 mg
Study: 27708111
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg plus ASA
Study: 23747777
Drug: Rivaroxaban (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (a factor Xa inhibitor)
Study: 23747777
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (dual antiplatelet therapy)
Study: 17375118
Drug: Virgin olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin olive oil (50 ml daily)
Study: 28892591
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg twice-weekly
Study: 10737480
Drug: BCG maintenance
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG maintenance therapy (intravesical and percutaneous BCG each week for 3 weeks at 3, 6, 12, 18, 24, 30, and 36 months)
Study: 10737480
Drug: No BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No BCG maintenance therapy
Study: 23452187
Drug: BCG maintenance
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG maintenance therapy
Study: 1578910
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation therapy (including allogeneic and autologous bone marrow transplantation)
Study: 1578910
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (3 gm/M2/day IV on days 1-6)
Study: 1578910
Drug: Conventional induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional induction therapy +/− GM-CSF